Journal
SEMINARS IN IMMUNOLOGY
Volume 28, Issue 3, Pages 250-259Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2016.04.007
Keywords
Complement; Kidney transplantation; Mirococept; Therapeutics
Categories
Funding
- Alexion
- MRC [G0000771, G1001197, MR/M012263/1] Funding Source: UKRI
- Medical Research Council [G1001197, MR/J006742/1, MR/M012263/1, G0000771] Funding Source: researchfish
Ask authors/readers for more resources
The part of the innate immune system that communicates and effectively primes the adaptive immune system was termed complement by Ehrlich to reflect its complementarity to antibodies having previously been described as alexine (i.e protective component of serum) by Buchner and Bordet. It has been established that complement is not solely produced systemically but may have origin in different tissues where it can influence organ specific functions that may affect the outcome of transplanted organs. This review looks at the role of complement in particular to kidney transplantation. We look at current literature to determine whether blockade of the peripheral or central compartments of complement production may prevent ischaemic reperfusion injury or rejection in the transplanted organ. We also review new therapeutics that have been developed to inhibit components of the complement cascade with varying degrees of success leading to an increase in our understanding of the multiple triggers of this complex system. In addition, we consider whether biomarkers in this field are effective markers of disease or treatment. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available